Close Menu

NEW YORK (GenomeWeb) – ERS Genomics said today that it has licensed its CRISPR-Cas9 genome editing technology to Lonza Pharma & Biotech for use in Lonza's bioproduction products and services and in induced pluripotent stem cells for research applications.

Financial terms of the agreement were not disclosed.

"We see tremendous potential for the use of gene editing to enhance the manufacturing of biologics and I expect Lonza will certainly be leading the way," ERS CEO Eric Rhodes said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.